Company intelligence / Profile preview

International Point of Care

Etobicoke, Ontario, Canada

Ownership: Private
Employees: ~192
Development stage: Other

Overview

International Point of Care develops and manufactures diagnostic components for global IVD leaders; their products—including lyophilized reagents, recombinant proteins, and blood separation membranes—are commercialized for rapid point-of-care and molecular diagnostics. The company is now part of Fortis Life Sciences, providing GMP/ISO 13485 contract manufacturing and advanced technologies for ultra-high-sensitivity and multiplex testing.

Modalities: DeviceBiologicMonoclonal antibodyRecombinant proteinLyophilized reagent
Industry: Contract Manufacturing Organization

Beyond the preview

Go deeper on International Point of Care.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on International Point of Care.

Explore the full profile